Medivir—winner of the SwedenBIO Award 2010

​Today, Medivir’s CEO Ron Long received the SwedenBIO Award 2010 from research and further education minister Tobias Krantz at life sciences industry organization SwedenBIO’s annual conference in Stockholm.

Medivir won the award for all the successes the company achieved in 2009. The citation for Medivir, worthy winner of the SwedenBIO Award 2010, reads as follows: 

Citation
During the year, management positioned the company to evolve from a research and development enterprise into a pharmaceutical company with proprietary products and its own Nordic sales organization. Its new cold sore product Xerclear™ is the first, and so far only, pharmaceutical able to demonstrate in clinical trials that it can prevent the incidence of cold sores, a condition affecting 2 million people in Sweden alone. Medivir secured market approval on its two key markets of the US and Europe in 2009, with unique competitive advantages. At the same time, the company built its own sales organization, while also achieving substantial advances in international partnerships with other companies, particularly in the hepatitis C segment. Perseverance, partnership and a global perspective are the core ingredients of Medivir’s recipe for success. 

“2009 was a year Medivir made a lot of progress on the road to becoming an established pharmaceutical company. It’s really stimulating from me and my colleagues to receive the SwedenBIO Award with this citation,” commented Medivir’s CEO Ron Long.

For financial information, please contact
Rein Piir, Medivir’s CFO and VP of Investor Relations,
Tel: +46 (0) 708-537 292.

For more information on Medivir, please visit the company’s website: www.medivir.se